Reticulate Pigmented Anomaly

Back

Background

Dowling[1] first delineated this genodermatosis as a distinct entity in 1938. In 1954, Degos and Ossipowski[2] described a patient with a similar case. Few patients with reticulate pigmented anomaly, also known as Dowling-Degos disease (DDD), have been reported.

Loss-of-function mutations were identified in the keratin 5 gene (KRT5) in all affected family members and in 6 unrelated patients with Dowling-Degos disease (reticulate pigmented anomaly). Another study found the same KRT5 mutation in patients with reticulate pigmented anomaly and its acantholytic variant, Galli-Galli disease.[3] This variant has a genotype/phenotype correlation with mutations in the keratin 5 (KRT5) gene.[4] In analyzing 5 patients lacking a KRT5 mutation, mutations in POGLUT1, encoding protein O-glucosyltransferase 1, were identified.[5] Additional POFUT1 mutations in Dowling-Degos disease have been documented.[6, 7, 8, 9]

Dowling-Degos disease (reticulate pigmented anomaly) is slowly progressive. It is characterized by pigmented filiform epidermal papules closely resembling an adenoid seborrheic keratosis, but similar proliferations also develop around the variably dilated pilosebaceous follicles.

Typical clinical Dowling-Degos disease (reticulate pigmented anomaly) may histopathologically be Galli-Galli disease.[10] Galli-Galli disease is a rare genodermatosis in the spectrum of reticulate hyperpigmentation, probably best regarded as an acantholytic variant of Dowling-Degos disease (reticulate pigmented anomaly).[11]

Pathophysiology

Dowling-Degos disease (reticulate pigmented anomaly) is often familial and appears to be inherited in an autosomal dominant manner.[12, 13] A gene locus believed responsible in one Chinese patient was mapped to 17p13.3.[14] A genome-wide linkage analysis of 2 German families mapped this disease to 12q.[15] This region includes the keratin gene cluster, which was screened for mutations.

Loss-of-function mutations were identified in the keratin 5 gene (KRT5) in all affected family members and in 6 unrelated patients with Dowling-Degos disease (reticulate pigmented anomaly). Another study found the same KRT5 mutation in patients with reticulate pigmented anomaly and its acantholytic variant, Galli-Galli disease.[3] This variant has a genotype/phenotype correlation with mutations in the keratin 5 (KRT5) gene.[4] In analyzing 5 patients lacking a KRT5 mutation, mutations in POGLUT1, encoding protein O-glucosyltransferase 1, were identified.[5] Additional POFUT1 mutations in Dowling-Degos disease have been documented.[6, 7]

A heterozygous frameshift mutation in the V1 domain of keratin 5 was identified in a family with Dowling-Degos disease (reticulate pigmented anomaly).[16] This study confirmed that haploinsufficiency for K5 causes Dowling-Degos disease (reticulate pigmented anomaly) and points to a prominent role for the keratin intermediate filament cytoskeleton within basal keratinocytes in epidermal pigment biology.

Etiology

See Pathophysiology. Dowling-Degos disease (reticulate pigmented anomaly) may coexist with hidradenitis suppurativa. The follicular occlusion inherent in Dowling-Degos disease (reticulate pigmented anomaly) may predispose to the development of hidradenitis suppurativa.[17, 18] PUVA therapy neither aggravates nor reveals Dowling-Degos disease,[19] although it was described in one patient after this treatment.

Epidemiology

Frequency

Dowling-Degos disease (reticulate pigmented anomaly) is a rare condition worldwide.

Sex

Dowling-Degos disease (reticulate pigmented anomaly) affects both sexes. Although Dowling-Degos disease (reticulate pigmented anomaly) appears to be inherited in an autosomal dominant manner,[20] a female predominance has been noted in some surveys.[21]

Age

Dowling-Degos disease (reticulate pigmented anomaly) tends to develop early in adult life, with the onset of pigmentation occurring in individuals before they are aged 24 years. A Chinese newborn with reticulate pigmented anomaly of the flexures was recently described.[22]

Prognosis

Dowling-Degos disease (reticulate pigmented anomaly) is slowly progressive but not life threatening.

Patient Education

The patient and his or her family should be educated about the common autosomal dominant nature of Dowling-Degos disease (reticulate pigmented anomaly).

History

A rare pigmentary disorder, Dowling-Degos disease (reticulate pigmented anomaly) is characterized by reticulate pigmentation of the flexures, prominent comedolike lesions and pitted scars.

Some patients report pruritus in the involved regions. Most patients in the authors' experience report increased pigmentation in the neck, the axillae, or the groin, with an onset varying from childhood to adult life. It has been described in one family as occurring together with dyschromatosis universalis hereditaria.[23]

A rare association has been described between hidradenitis suppurativa and Dowling-Degos disease (reticulate pigmented anomaly), in one case together with multiple epidermal cysts. This may reflect a single underlying defect of follicular proliferation.[24]

Physical Examination

The flexural pigmentation has its onset from childhood to adult life. It may be intense, with a brownish black color and sometimes steel blue or navy overtones. It may be generalized with truncal involvement, or be less severe, with stippled shades of brown. Rarely, the macules may be hypopigmented.[25, 26]

No verrucous or velvety papillomatosis is present, as might be seen in acanthosis nigricans. If the patches are palpable, it is because of lichenification that produces a glossy and at times somewhat wrinkled appearance. The margins may show tiny pigmented comedones.

In some cases of Dowling-Degos disease (reticulate pigmented anomaly), comedolike papules may be present on the back and/or neck. Dowling-Degos disease with follicular localization has been characterized as an uncommon variant of this evolving dermatosis.[27] Some patients with Dowling-Degos disease (reticulate pigmented anomaly) have pitted perioral scars.

In addition, speckled macules involving the dorsum of the hands, the proximal nail folds, or the scrotum[28] may be seen. It may begin as numerous pigmented macules on the axillary and anogenital skin.[29] There may be diffuse penile pigmentation.[30] Fingernail dystrophy may be present.[21] The finding of speckled macules on the scrotum is isolated and limited to the scrotal and penile skin.[28] This pigmented eruption on the male external genitalia is possibly a cutaneous marker of underlying testicular carcinoma. In female patients, speckled macules may be found on the vulva.[31, 32, 33] Note the image below.



View Image

Speckled macules on the male external genitalia.

Approach Considerations

The dermoscopic findings of Dowling-Degos disease (reticulate pigmented anomaly) are not specific, but they may be useful in selected patients to rule out melanoma of the vulva.[32]

In some patients, molecular genetic analysis can facilitate making the diagnosis.[43]

Histologic Findings

Histopathologically in Dowling-Degos disease (reticulate pigmented anomaly), pigmented rete ridge elongation with thinning of the suprapapillary epithelium, dermal melanosis, and perivascular lymphohistiocytic infiltration is present. The downward elongations are composed of regular pigmented basaloid cells.

A small study showed all pigmented cells in the basal layer were recognized by anti-PEP-1, anti-PEP-2, HMB-45, and NKI/beteb antibodies.[44] Supranuclear "caps" of brown granules were observed within most basal keratinocytes in the hyperpigmentation area. The melanocytes contained regular melanosomes in all stages of maturation in their cytoplasms. Melanosomes, mainly of stages III and IV, were evident within keratinocytes, distributed either as scattered patterns or forming caps over the nucleus. Note the image below.



View Image

Histologic view showing elongated thin rete ridges with melanin concentrated at the tips (hematoxylin and eosin).

Medical Care

No treatment is effective for Dowling-Degos disease (reticulate pigmented anomaly).[21] Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. Pruritus may respond well to H1 antihistamines.[43]

Surgical Care

Dowling-Degos disease (reticulate pigmented anomaly) has been successfully treated with the fractional Er:YAG laser[45] and a combination of Q-switched Nd: YAG and fractional carbon dioxide laser.[46] One patient responded favorably to the use of intense pulsed light.[47]

Author

Robert A Schwartz, MD, MPH, Professor and Head of Dermatology, Professor of Pathology, Professor of Pediatrics, Professor of Medicine, Rutgers New Jersey Medical School

Disclosure: Nothing to disclose.

Specialty Editors

David F Butler, MD, Former Section Chief of Dermatology, Central Texas Veterans Healthcare System; Professor of Dermatology, Texas A&M University College of Medicine; Founding Chair, Department of Dermatology, Scott and White Clinic

Disclosure: Nothing to disclose.

Warren R Heymann, MD, Head, Division of Dermatology, Professor, Department of Internal Medicine, Rutgers New Jersey Medical School

Disclosure: Nothing to disclose.

Chief Editor

William D James, MD, Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

Disclosure: Received income in an amount equal to or greater than $250 from: Elsevier; WebMD.

Acknowledgements

Mark A Crowe, MD Assistant Clinical Instructor, Department of Medicine, Division of Dermatology, University of Washington School of Medicine

Mark A Crowe, MD is a member of the following medical societies: American Academy of Dermatology and North American Clinical Dermatologic Society

Disclosure: Nothing to disclose.

Borys Savchyk, MD, PhD Director, Molecular Biology Institute, Medical University of Lviv, Ukraine

Disclosure: Nothing to disclose.

Alexander Zajchenko, MD Head, Professor, Department of Skin and Venereal Diseases, Medical University of Lviv, Ukraine

Disclosure: Nothing to disclose.

References

  1. Dowling GD, Freudenthal W. Acanthosis nigricans. Proc Roy Soc Med. 1938. 31:1147-50.
  2. Degos R, Ossipowski B. [Reticulated pigmentary dermatosis of the folds: relation to acanthosis nigricans.]. Ann Dermatol Syphiligr (Paris). 1954 Mar-Apr. 81(2):147-51. [View Abstract]
  3. Hanneken S, Rütten A, Pasternack SM, Eigelshoven S, El Shabrawi-Caelen L, Wenzel J, et al. Systematic mutation screening of KRT5 supports the hypothesis that Galli-Galli disease is a variant of Dowling-Degos disease. Br J Dermatol. 2010 Mar 5. [View Abstract]
  4. Hanneken S, Rütten A, Eigelshoven S, Braun-Falco M, Pasternack SM, Ruzicka T, et al. [Galli-Galli disease. Clinical and histopathological investigation using a case series of 18 patients]. Hautarzt. 2011 Nov. 62(11):842-51. [View Abstract]
  5. Basmanav FB, Oprisoreanu AM, Pasternack SM, Thiele H, Fritz G, Wenzel J, et al. Mutations in POGLUT1, encoding protein O-glucosyltransferase 1, cause autosomal-dominant Dowling-Degos disease. Am J Hum Genet. 2014 Jan 2. 94(1):135-43. [View Abstract]
  6. Basmanav FB, Fritz G, Lestringant GG, Pachat D, Hoffjan S, Fischer J, et al. Pathogenicity of POFUT1 in Dowling-Degos disease: additional mutations and clinical overlap with reticulate acropigmentation of kitamura. J Invest Dermatol. 2015 Feb. 135(2):615-8. [View Abstract]
  7. Kono M, Suganuma M, Takama H, Zarzoso I, Saritha M, Bodet D, et al. Dowling-Degos disease with mutations in POFUT1 is clinico-pathologically distinct from reticulate acropigmentation of Kitamura. Br J Dermatol. 2015 Feb 1. [View Abstract]
  8. Duchatelet S, Clerc H, Machet L, Gaboriaud P, Miskinyte S, Kervarrec T, et al. A new nonsense mutation in the POGLUT1 gene in two sisters with Dowling-Degos disease. J Eur Acad Dermatol Venereol. 2018 Mar 23. [View Abstract]
  9. Kono M, Sawada M, Nakazawa Y, Ogi T, Muro Y, Akiyama M. A Japanese Case of Galli-Galli Disease due to a Previously Unreported POGLUT1 Mutation. Acta Derm Venereol. 2019 Apr 1. 99 (4):458-459. [View Abstract]
  10. Müller CS, Pföhler C, Tilgen W. Changing a concept--controversy on the confusing spectrum of the reticulate pigmented disorders of the skin. J Cutan Pathol. 2009 Jan. 36(1):44-8. [View Abstract]
  11. El Shabrawi-Caelen L, Rütten A, Kerl H. The expanding spectrum of Galli-Galli disease. J Am Acad Dermatol. 2007 May. 56(5 Suppl):S86-91. [View Abstract]
  12. Brown WG. Reticulate pigmented anomaly of the flexures. Case reports and genetic investigation. Arch Dermatol. 1982 Jul. 118(7):490-3. [View Abstract]
  13. Yu W, Gan L, Wu J, Sun J, Jiang Y. Dowling-Degos disease with mutation in the exon 1 of the keratin 5 gene. J Eur Acad Dermatol Venereol. 2017 Jun 24. [View Abstract]
  14. Li CR, Xing QH, Li M, et al. A gene locus responsible for reticulate pigmented anomaly of the flexures maps to chromosome 17p13.3. J Invest Dermatol. 2006 Jun. 126(6):1297-301. [View Abstract]
  15. Betz RC, Planko L, Eigelshoven S, et al. Loss-of-function mutations in the keratin 5 gene lead to Dowling-Degos disease. Am J Hum Genet. 2006 Mar. 78(3):510-9. [View Abstract]
  16. Liao H, Zhao Y, Baty DU, McGrath JA, Mellerio JE, McLean WH. A heterozygous frameshift mutation in the V1 domain of keratin 5 in a family with Dowling-Degos disease. J Invest Dermatol. 2007 Feb. 127(2):298-300. [View Abstract]
  17. Bedlow AJ, Mortimer PS. Dowling-Degos disease associated with hidradenitis suppurativa. Clin Exp Dermatol. 1996 Jul. 21(4):305-6. [View Abstract]
  18. Fenske NA, Groover CE, Lober CW, Espinoza CG. Dowling-Degos disease, hidradenitis suppurativa, and multiple keratoacanthomas. A disorder that may be caused by a single underlying defect in pilosebaceous epithelial proliferation. J Am Acad Dermatol. 1991 May. 24(5 Pt 2):888-92. [View Abstract]
  19. Khaddar RK, Mahjoub WK, Zaraa I, Sassi MB, Osman AB, Debbiche AC, et al. [Extensive Dowling-Degos disease following long term PUVA therapy]. Ann Dermatol Venereol. 2012 Jan. 139(1):54-7. [View Abstract]
  20. Jones EW, Grice K. Reticulate pigmented anomaly of the flexures. Dowing Degos disease, a new genodermatosis. Arch Dermatol. 1978 Aug. 114(8):1150-7. [View Abstract]
  21. Kim YC, Davis MD, Schanbacher CF, Su WP. Dowling-Degos disease (reticulate pigmented anomaly of the flexures): a clinical and histopathologic study of 6 cases. J Am Acad Dermatol. 1999 Mar. 40(3):462-7. [View Abstract]
  22. Zuo YG, Ho M, Jin HZ, Wang BX. Case report: a case of newborn onset reticulate pigmented anomaly of the flexures in a Chinese female. J Eur Acad Dermatol Venereol. 2008 Jul. 22(7):901-3. [View Abstract]
  23. Sandhu K, Saraswat A, Kanwar AJ. Dowling-Degos disease with dyschromatosis universalis hereditaria-like pigmentation in a family. J Eur Acad Dermatol Venereol. 2004 Nov. 18(6):702-4. [View Abstract]
  24. Loo WJ, Rytina E, Todd PM. Hidradenitis suppurativa, Dowling-Degos and multiple epidermal cysts: a new follicular occlusion triad. Clin Exp Dermatol. 2004 Nov. 29(6):622-4. [View Abstract]
  25. Naveen KN, Athaniker SB, Hegde SP, Shetty R, Radha H, Parinitha SS. Atypical cases of Dowling-Degos disease. Indian Dermatol Online J. 2016 Mar-Apr. 7 (2):99-102. [View Abstract]
  26. Ghosh A, Kumar P, Das A. Generalized Dowling-Degos disease with hypopigmented lesions: A diagnostic challenge. Indian J Dermatol Venereol Leprol. 2018 Jan-Feb. 84 (1):70-72. [View Abstract]
  27. Singh S, Khandpur S, Verma P, Singh M. Follicular Dowling Degos disease: a rare variant of an evolving dermatosis. Indian J Dermatol Venereol Leprol. 2013 Nov-Dec. 79(6):802-4. [View Abstract]
  28. Schwartz RA, Birnkrant AP, Burgess GH, Stoll HL Jr, Yaqub M, Fox MD. Reticulate pigmented anomaly. Cutis. 1980 Oct. 26(4):380-1. [View Abstract]
  29. Batycka-Baran A, Baran W, Hryncewicz-Gwozdz A, Burgdorf W. Dowling-Degos disease: case report and review of the literature. Dermatology. 2010. 220(3):254-8. [View Abstract]
  30. Taskapan O, Gokce E, Akin O, Erkilinc AC, Demirkesen C. Dowling-Degos disease with diffuse penile pigmentation. J Eur Acad Dermatol Venereol. 2014 Jan 15. [View Abstract]
  31. O'Goshi K, Terui T, Tagami H. Dowling-Degos disease affecting the vulva. Acta Derm Venereol. 2001 May. 81(2):148. [View Abstract]
  32. Massone C, Hofmann-Wellenhof R. Dermoscopy of Dowling-Degos disease of the vulva. Arch Dermatol. 2008 Mar. 144(3):417-8. [View Abstract]
  33. Coco V, Guerriero C, Esposito I, De Vincenzo RP, Peris K. A familial case of Dowling-Degos disease on the vulva. Clin Exp Dermatol. 2019 Jan 21. [View Abstract]
  34. Lee SJ, Lee HJ, Kim DW, Jun JB, Chung SL, Bae HI. A case of Dowling-Degos disease suggesting an evolutional sequence. J Dermatol. 2000 Sep. 27(9):591-7. [View Abstract]
  35. Nishizawa A, Nakano H, Satoh T, Takayama K, Sawamura D, Yokozeki H. Haber's syndrome may be a clinical entity different from Dowling-Degos disease. Br J Dermatol. 2009 Jan. 160(1):215-7. [View Abstract]
  36. Braun-Falco M, Volgger W, Borelli S, Ring J, Disch R. Galli-Galli disease: an unrecognized entity or an acantholytic variant of Dowling-Degos disease?. J Am Acad Dermatol. 2001 Nov. 45(5):760-3. [View Abstract]
  37. Gilchrist H, Jackson S, Morse L, Nicotri T, Nesbitt LT. Galli-Galli disease: A case report with review of the literature. J Am Acad Dermatol. 2008 Feb. 58(2):299-302. [View Abstract]
  38. Ee HL, Tan SH. Reticulate hyperpigmented scleroderma: a new pigmentary manifestation. Clin Exp Dermatol. 2005 Mar. 30(2):131-3. [View Abstract]
  39. Shen Z, Chen L, Ye Q, Hao F, Vitorino Mdos S, Yang X, et al. Coexistent Dowling-Degos disease and reticulate acropigmentation of kitamura with progressive seborrheic keratosis. Cutis. 2011 Feb. 87(2):73-5. [View Abstract]
  40. Rongioletti F, Fausti V, Christana K, Montinari M, Parodi A, Fiocca R. Atypical Variant of Galli-Galli Disease (Grover-Like Eruption With Lentiginous Freckling) in a Liver Transplant Patient. Am J Dermatopathol. 2011 Jan 19. [View Abstract]
  41. Müller CS, Tremezaygues L, Pföhler C, Vogt T. The spectrum of reticulate pigment disorders of the skin revisited. Eur J Dermatol. 2012 Sep-Oct. 22(5):596-604. [View Abstract]
  42. Strausburg M, Linos K, Staser K, Mousdicas N. Dowling-Degos disease co-presenting with Darier disease. Clin Exp Dermatol. 2016 Jun. 41 (4):410-2. [View Abstract]
  43. Knuever J, Persa OD, Illerhaus A, Ralser DJ, Hartmann K, Betz RC, et al. Mast cell activation in Dowling-Degos disease. Br J Dermatol. 2019 Dec. 181 (6):1312-1314. [View Abstract]
  44. Zhang RZ, Zhu WY. A study of immunohistochemical and electron microscopic changes in Dowling-Degos disease. J Dermatol. 2005 Jan. 32(1):12-8. [View Abstract]
  45. Yun JH, Kim JH, Choi JS, Roh JY, Lee JR. Treatment of Dowling-Degos disease with fractional Er:YAG laser. J Cosmet Laser Ther. 2013 Mar 6. [View Abstract]
  46. Tambe SA, Patil PD, Saple DG. Successful Management of Dowling-Degos Disease with Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser. J Cutan Aesthet Surg. 2017 Jan-Mar. 10 (1):60-62. [View Abstract]
  47. Gupta A, Huilgol SC. Successful treatment of Dowling-Degos disease using intense pulsed light. Australas J Dermatol. 2014 Dec 13. [View Abstract]
  48. Drut R, Pollono D, Drut RM. Bilateral nephroblastoma in familial Hay-Wells syndrome associated with familial reticulate pigmentation of the skin. Am J Med Genet. 2002 Jun 15. 110(2):164-9. [View Abstract]

Speckled macules on the male external genitalia.

Histologic view showing elongated thin rete ridges with melanin concentrated at the tips (hematoxylin and eosin).

Speckled macules on the male external genitalia.

Histologic view showing elongated thin rete ridges with melanin concentrated at the tips (hematoxylin and eosin).